Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MiNK Therapeutics

< Previous 1 2 Next >
MiNK Reports Fourth Quarter and Year-End 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Third Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in September Investor Conferences
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Second Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Host R&D Event November 10, 2022
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.